How to buy Immunic stock

Immunic, Inc is a biotechnology business based in the US. Immunic shares (IMUX) are listed on the NASDAQ and all prices are listed in US Dollars. Immunic employs 28 staff and has a market cap (total outstanding shares value) of 0.00.

Immunic share price

Use our graph to track the performance of IMUX stocks over time.

Immunic shares at a glance

• Key figures

Information last updated 2021-04-29.

52-week range	$7.50 - $28.21
50-day moving average	$15.02
200-day moving average	$17.01
Wall St. target price	$59.38
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-11.31

Buy Immunic shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Immunic stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Immunic, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Immunic financials

Gross profit TTM	$0
Return on assets TTM	-26.18%
Return on equity TTM	-40.54%
Profit margin	0%
Book value	$7.50
Market capitalisation	$328 million

TTM: trailing 12 months

Shorting Immunic shares

There are currently 1.5 million Immunic shares held short by investors – that's known as Immunic's "short interest". This figure is 2.3% up from 1.4 million last month.

There are a few different ways that this level of interest in shorting Immunic shares can be evaluated.

Immunic's "short interest ratio" (SIR)

Immunic's "short interest ratio" (SIR) is the quantity of Immunic shares currently shorted divided by the average quantity of Immunic shares traded daily (recently around 160549.50276243). Immunic's SIR currently stands at 9.05. In other words for every 100,000 Immunic shares traded daily on the market, roughly 9050 shares are currently held short.

However Immunic's short interest can also be evaluated against the total number of Immunic shares, or, against the total number of tradable Immunic shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Immunic's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Immunic shares in existence, roughly 70 shares are currently held short) or 0.0979% of the tradable shares (for every 100,000 tradable Immunic shares, roughly 98 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Immunic.

Find out more about how you can short Immunic stock.

Immunic share dividends

We're not expecting Immunic to pay a dividend over the next 12 months.

Have Immunic's shares ever split?

Immunic's shares were split on a 1:40 basis on 14 April 2019. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Immunic shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for Immunic shares which in turn could have impacted Immunic's share price.

Immunic share price volatility

Over the last 12 months, Immunic's shares have ranged in value from as little as $7.5 up to $28.214. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Immunic's is 2.0276. This would suggest that Immunic's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Immunic overview

Immunic, Inc. , a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York. .

Frequently asked questions

• What percentage of Immunic is owned by insiders or institutions?

  Currently 29.665% of Immunic shares are held by insiders and 45.854% by institutions.

• How many people work for Immunic?

  Latest data suggests 28 work at Immunic.

• When does the fiscal year end for Immunic?

  Immunic's fiscal year ends in December.

• Where is Immunic based?

  Immunic's address is: 1200 Avenue of the Americas, New York, NY, United States, 10036

• What is Immunic's ISIN number?

  Immunic's international securities identification number is: US4525EP1011

• What is Immunic's CUSIP number?

  Immunic's Committee on Uniform Securities Identification Procedures number is: 4525EP101